TFX's Quality Score fell 1 point on Tue, Nov 3, to 8.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 61% over five years while the S&P 500 rose 74%; up 16% in the past year.
| The company | Sales up 31% on the year |
| Latest filing | 10-Q, Aug 6 |
ReportReports Thursday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +0.4% on average. Past reports ›
After its last 4 reports it closed +0.4% on average, higher 3 of 4 times.
Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
TFX is #24 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 24 |
Net income over four quarters: TFX -$1.03B, MMSI $146M, GMED $535M, INSP $135M.
Reports Thu Nov 5, before the open (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Importantly, the delay is attributable to elongated integration timelines and not the underlying product portfolio, which remains competitively well positioned.”
TFX's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| GAAP revenue growth from continuing operations | 13.4% to 14.4% |
Sales fell 4.7% a year over 5 years, fiscal 2020 to 2025.
Pays $1.36 a share a year.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | +3.2% | +1.5% | -0.3% |
| May 7, 2026 | +5.2% | +6.9% | +5.5% |
| Feb 26, 2026 | -3.0% | +6.4% | +6.5% |
Sales grew in three of the last seven years, to $2B in 2025. It lost money in 2025 after a profit in 2024.
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: TFX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
“The medical device industry is highly competitive.”
TFX scores 8 today, which Breakaway calls Average. It is #24 of 85 in Medical Devices by Quality Score, with 6 of 14 chart checks firing. Down 61% over five years while the S&P 500 rose 74%; up 16% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
TFX scores 8 today, which Breakaway calls Average (6 to 10). That is #24 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TFX's 8.
Reports Thu Nov 5, before the open, a date the company confirmed. TFX closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.